[Discussion] we are measuring state board at the wrong time and calling it noise
we are measuring state board at the wrong time and calling it noise. I have gone back and forth on this for months. The five questions worth asking before you commit to any compounded arrangement. Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the…
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Compounded preparations are not approved products and carry no bioequivalence claim.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Is the compound still on the shortage list where you are?
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Correction: patient-specific refers to the prescription, not to a bespoke formulation.
This is the distinction the whole board runs on. Everything else follows from it.
the API source is the question nobody asks and everybody should